Eikon Therapeutics filings document its transition to a Nasdaq-listed public company, its common stock registration, governance documents, financial results, and clinical and corporate updates. The company’s Form 8-K disclosures include results of operations and financial condition, exhibits containing press releases, and amendments to its certificate of incorporation and bylaws in connection with its initial public offering.
The filings also identify Eikon’s common stock, par value, trading symbol, Nasdaq listing, and public-company governance framework. For this clinical-stage biopharmaceutical issuer, regulatory disclosures center on capital structure, shareholder matters, clinical program updates, and corporate reporting obligations.
Eikon Therapeutics ownership update: Abu Dhabi Investment Authority reports beneficial ownership of 2,816,714 shares of common stock, representing 5.2% of the class. The filing cites a shares outstanding base of 53,984,337 after giving effect to the offering described in the prospectus filed pursuant to Rule 424(b)(4) on February 5, 2026.
Platinum Falcon B 2018 RSC Limited is reported as the direct owner of 1,147,138 shares (shown as 2.1% of the class); Platinum Falcon is a wholly owned subsidiary of Abu Dhabi Investment Authority and certain voting/dispositive powers are shared between them.
The Column Group investment entities and principals have disclosed a large ownership position in Eikon Therapeutics, Inc. common stock. Together, they report beneficial ownership of 6,353,712 shares, representing 11.6% of Eikon’s outstanding common stock.
The stake is held through multiple venture funds and includes shares underlying warrants exercisable within 60 days. The position stems from preferred stock investments made between 2019 and 2025 that converted into common stock at Eikon’s initial public offering, plus additional common shares purchased in the IPO at $18 per share.
The investors describe their holdings as for general investment purposes and may increase or decrease their position over time. They also hold registration rights under an investors’ rights agreement and have agreed to 180-day lock-up restrictions following the IPO underwriting agreement.
Eikon Therapeutics, Inc. received a Schedule 13G filing from a group of Foresite Capital investment funds and their affiliated managers, disclosing a significant passive ownership stake in its common stock. The filing reports that various Foresite Capital funds and entities collectively attribute beneficial ownership to James B. Tananbaum of 4,148,519 shares, representing 7.7% of the common stock, based on 53,984,337 shares outstanding as of February 4, 2026.
Individual Foresite vehicles report smaller positions, including Foresite Capital Fund IV, L.P. with 1,960,774 shares (3.6%), Foresite Capital Fund V, L.P. with 1,353,168 shares (2.5%), Foresite Capital Opportunity Fund V, L.P. with 425,852 shares (0.8%), and Foresite Capital VI-A, LLC with 408,725 shares (0.8%). Each entity reports sole voting and dispositive power over its shares, with those powers ultimately attributable to Tananbaum through the general partner and managing member structures.
The Reporting Persons certify that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Eikon Therapeutics, indicating a passive investment posture consistent with a Schedule 13G filing.
Eikon Therapeutics, Inc. insider Roger M. Perlmutter, the company’s Chief Executive Officer and Director, indirectly acquired 284,857 shares of common stock on February 6, 2026 through derivative conversions tied to the company’s initial public offering.
Series A-1 Preferred Stock representing 1,268,891 shares and Series D Preferred Stock representing 855,512 shares each converted into common stock immediately prior to the IPO closing on a 1-for-7.4578 basis. The resulting common shares are held indirectly for Perlmutter’s benefit through Perlmutter Consulting, Inc., in which he had the sole pecuniary interest.
Entities affiliated with The Column Group reported sizable ownership changes in Eikon Therapeutics, Inc. (EIKN) tied to the company’s initial public offering. On February 6, 2026, multiple funds converted preferred stock into common and also bought additional shares.
The Column Group IV, LP, IV-A, LP and Opportunity III, LP converted Series A, A-1, C-1 and D preferred shares into common stock at an approximate 0.1340878-to-1 ratio and now hold indirect positions including 4,312,139, 148,840 and 1,319,164 common shares, respectively. On the same date, these entities also made open-market purchases of 1,437,323, 49,556 and 630,881 common shares at $18 per share. The filing states that the reporting persons disclaim beneficial ownership beyond their pecuniary interest.
Foresite Capital Management IV, LLC reported multiple insider transaction types in a Form 4 filing for EIKN. The filing lists transactions totaling 34,239,351 shares at a weighted average price of $18.00 per share. Following the reported transactions, holdings were 1,943,682 shares.
Eikon Therapeutics director Kenneth C. Frazier bought 111,111 shares of the company’s common stock in an open-market transaction. The purchase took place on February 4, 2026 at a price of $18 per share, and he now directly holds 111,111 shares.
Lux-affiliated investment funds associated with Eikon Therapeutics director and 10% owner Josh Wolfe reported significant share activity around the company’s IPO. On February 4, 2026, Lux Co-Invest Opportunities II and Lux Total Opportunities each bought 138,888 Eikon common shares in open-market transactions at $18 per share, held indirectly through their general partners.
On February 6, 2026, multiple series of Lux-held preferred stock automatically converted into Eikon common stock immediately prior to the IPO at a 1-for-7.4578 conversion rate. This resulted in indirect common stock positions including 2,387,705 shares held for Lux Ventures V, 1,290,428 shares held for a Lux Co-Invest vehicle, and 2,294,653 shares held for a Lux Total Opportunities fund. Voting and dispositive power is exercised by Lux general partner entities; Wolfe and Peter Hebert may be deemed beneficial owners through those entities, while each disclaims beneficial ownership beyond their pecuniary interest.
Eikon Therapeutics, Inc. reported insider transactions by Lux-affiliated investment entities related to its IPO. On February 4, 2026, Lux Co-Invest Opportunities II, L.P. and Lux Total Opportunities, L.P. each indirectly bought 138,888 shares of common stock at $18 per share in open-market purchases.
On February 6, 2026, several Lux funds indirectly acquired common stock through conversions of preferred stock, including 10,000,000 shares of Series A Preferred Stock and multiple series of A-1, B, B-1, C, C-1 and D Preferred Stock. These preferred shares converted into common stock immediately prior to the closing of Eikon’s initial public offering on a 1-for-7.4578 basis. The Lux entities report indirect beneficial ownership, and the managing members, including director Josh Wolfe and Peter Hebert, disclaim beneficial ownership except to the extent of their pecuniary interests.
Eikon Therapeutics, Inc. reported that, in connection with the closing of its initial public offering on February 6, 2026, it put in place a new legal and governance framework. Immediately prior to the IPO closing, the company’s board and stockholders approved an amended and restated certificate of incorporation and amended and restated bylaws.
The restated certificate of incorporation was filed with the Delaware Secretary of State, and the updated bylaws became effective on February 6, 2026. These documents define the company’s capital structure and core governance rules as a newly public company whose common stock trades on the Nasdaq Stock Market under the symbol EIKN.